Co-Diagnostics (CODX) is a safe bet for short-term investors
Co-Diagnostics (CODX) currently trades at $9.22 and has grown by 1.43% today. Co-Diagnostics has said its tests can produce results in less than two hours. And it says they cost less for hospitals and other health-care organizations to run because the reagents used in the testing process cost less. “It is a significant step in opening more doors and helping this test to reach an even wider audience,” Chief Executive Dwight Egan said in a statement. The tests are designed to be used by certified laboratories, not by consumers themselves.
Based on this information, investorsQ rates this stock 5 out of 10. We give it this rating based on current information written in this article. The high forecast for Co-Diagnostics is $20.00 and the low is $5.00. Notably, the company’s market cap is $252.99 million with a 52 week high of $21.75 and a 52 week low of $0.69. CODX went up to $0.13 from the previous closing price of $9.09. CODX has changed in price by 8.15 per share in the last 12 months.
Co-Diagnostics, Inc. is a molecular diagnostics company with unique, patented Polymerase Chain Reaction (“PCR”) testing technology. A Utah corporation headquartered in Salt Lake City, Utah, we commercialize our innovative patented and patent-pending technology through sales, development and licensing, to quickly develop molecular diagnostics that are more cost-efficient and perform better than traditional technologies of the past.